|
Ipilimumab for metastatic melanoma (2012)
|
• Pay for performance with rebates payable should 2 year overall survival rates in real world clinical practice in Australia not align with clinical trial data
|
|
Ivacaftor for cystic fibrosis (2014)
|
• Pay for performance with rebates applicable for patients subsequently assessed as non-responders
|
|
Eculizumab for atypical haemolytic uraemic syndrome (2014)
|
• Pay for performance with rebates applicable for patients who do not achieve an agreed clinical outcome over an agreed time periods
|
|
Trametinib for metastatic melanoma (2014)
|
• Pay for performance with rebates applicable should trametinib fail to deliver claimed benefits
|
|
Crizotinib for non-small cell lung cancer (2014)
|
• Pay for performance with rebates applicable should crizotinib fail to deliver claimed benefits
|
|
Pembrolizumab for metastatic melanoma (2015)
|
• PBS list with provision for future clinical trial evidence to support a potential price increase
|
|
Nivolumab for non-small cell lung cancer (2016)
|
• PBS list with provision of future evidence to confirm effectiveness of nivolumab in NSCLC patients ≥75 years of age
|
